No matter how big or small, every action has an impact

That’s what we believe at Pharmanovia. We put patients and their families at the heart of our thinking, to see how we can enhance established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences.

We continually assess our portfolio, taking the patient and clinician insights we gather to identify different therapies and treatment options, originating from both in-house development and through strategic partnerships.

Pill icon

Portfolio of iconic brands growing through operational and commercial excellence

Beaker icon

Redevelopment of our portfolio using our life cycle management expertise

Document icon

In-licensing of novel therapies that complement our portfolio

Certificate icon

Targeted selection of acquisition candidates suitable for re-engineering

Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally

By 2025, we will be one of the world’s fastest growing global specialty pharma companies, launching value-added medicines in defined disease areas.

Leadership team

Motivated by a team of inquisitive minds

Our committed team refuse to accept how things have always been done and constantly seek to identify new ways to make a positive difference for patients.

Our capabilities

Chart icon

Product & Corporate Development

We target improved health outcomes through portfolio repurposing, re-engineering and rediscovery of existing medicines. We complement this through targeted acquisition and in-licensing of supportive therapies.

Cart icon


We market and promote our products globally through tailored go to market approaches, from in-house sales force to strategic distributor partnerships.

Chain icon

Supply Chain

We have strategic alliances with leading global Contract Manufacturing Organisations (CMOs) coupled with end-end Good Distribution Practice (GDP) logistics.

Document icon

Regulatory, Quality & Technical

We take an evidence based approach to bring products to market with significant in-house experience across clinical, medical, regulatory, quality, pricing and reimbursement.

Our behaviours graphic

Underpinned by our core behaviours

We are committed
We are agile
We are innovative

Careers at Pharmanovia

Acting responsibly

We are committed to working in a sustainable and ethical way, doing the right thing for people, communities and the environment.

Find out more

Global reach, local expertise

  • Our markets
  • Our headquarters
  • Our offices
Map of locations Map of locations

Partnering with us

Find out more

Our history


Our founder, Dr. Amit Patel and family founds Atnahs, named in honour of their grandmother, Shanta.

Headquartered in Basildon, UK.


We acquired Dipentum® from UCB.

We opened an office in Sydney, Australia to service our Australasian markets.


We acquired Anaprox®, Naprosyn® and Toradol® in certain territories from Roche.


We acquired US rights to Naproxen Suspension from Pediapharm.

We also acquired a majority stake in Danish company, Pharmanovia.


We acquired Bondronat®, Bonviva® and Kytril® in certain markets from Roche.

We opened an office in Vadodara, India to serve as our “Centre of Excellence” for Product Development.


We acquired Famvir® in certain territories from Novartis.

We acquired the remainder of Danish business, Pharmanovia.


We acquired Synacthen® from Mallinckrodt in certain territories.

Triton invests in Pharmanovia, supporting our future growth strategy.


We acquired Inderal®, Tenoretic®, Tenormin®, Zestoretic® and Zestril® in certain territories from AstraZeneca.

We acquired Rocaltrol® in certain territories from Roche.

Acquisition of the rights to Bonviva® in six South Asian markets.

We acquired Valium® from Roche in certain territories.


We rebranded Atnahs to Pharmanovia, the speciality pharma business that we acquired.

We opened offices in Switzerland, Italy, Singapore, Kuala Lumpur and South Korea.

We acquired Leustatin® from J&J.

We established our first global charity partnership with HIPZ.

James Burt joined Pharmanovia as CEO.


We rebranded Lamepro B.V which we aquired in 2020 to Pharmanovia, establishing an office in the Netherlands.

We launched our inaugural Sustainability Report.

We expanded our operations in China with the acquisition of Rocaltrol® from Roche.

We entered into an exclusive in-licensing agreement with Aquestive Therapeutics for Diazepam Buccal Film in certain territories.


We entered into an exclusive in-license agreement with Axsome Therapeutics, Inc. for Sunosi® across Europe, Middle East and North Africa (MENA).